Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy

被引：28
作者：
Inoue, Takako [1 ]
Watanabe, Takehisa [2 ]
Tanaka, Yasuhito [2 ,3 ,4 ]
机构：
[1] Nagoya City Univ Hosp, Dept Clin Lab Med, Nagoya, Japan
[2] Kumamoto Univ, Fac Life Sci, Dept Gastroenterol & Hepatol, 1-1-1 Honjo,Chuo Ku, Kumamoto 8608556, Japan
[3] Nagoya City Univ, Grad Sch Med Sci, Dept Virol, Nagoya, Japan
[4] Nagoya City Univ, Liver unit, Grad Sch Med Sci, Nagoya, Japan
来源：
CLINICAL AND MOLECULAR HEPATOLOGY | 2023年 / 29卷 / 04期
关键词：
Hepatitis B core-related antigen (HBcrAg); Covalently closed circular DNA (cccDNA); HBV reactivation; Point-of-care testing; RNA destabilizer; ANTISENSE OLIGONUCLEOTIDE BEPIROVIRSEN; NUCLEOS(T)IDE ANALOG THERAPY; CLOSED CIRCULAR DNA; HEPATOCELLULAR-CARCINOMA; ENZYME-IMMUNOASSAY; SURFACE-ANTIGEN; HBSAG; HBCRAG; RISK; REACTIVATION;
D O I：
10.3350/cmh.2022.0434
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
The current requirement for biomarkers to detect hepatitis B virus (HBV) infection is polarized. One is a fully-automated and highly sensitive measurement system; the other is a simple system for point-of-care testing (POCT) in resource limited areas. Hepatitis B core-related antigen (HBcrAg) reflects intrahepatic covalently closed circular DNA and serum HBV DNA. Even in patients with undetectable serum HBV DNA or HBsAg loss, HBcrAg may remain detectable. Decreased HBcrAg levels are associated with reduction of the occurrence of hepatocellular carcinoma (HCC) in chronic hepatitis B. Recently, a fully-automated, novel high-sensitivity HBcrAg assay (iTACT-HBcrAg, cut-off value: 2.1 logIU/mL) has been developed. This attractive assay has been released in Japan very recently. iTACT-HBcrAg can be useful for monitoring HBV reactivation and prediction of HCC occurrence, as an alternative to HBV DNA. Moreover, monitoring HBcrAg may be suitable for determining the therapeutic effectiveness of approved drugs and novel drugs under development. Presently, international guidelines recommend anti-HBV prophylaxis for pregnant women with high viral loads to prevent mother to-child transmission of HBV. However, >95% of HBV-infected individuals live in countries where HBV DNA quantification is not available. Worldwide elimination of HBV needs the scaling-up of examination and medication services in resource limited areas. Based on this situation, a rapid and easy HBcrAg assay as a POCT is valuable. This review provides the latest information regarding the clinical use of a new surrogate marker, HBcrAg, in HBV management, based on iTACT-HBcrAg or POCT, and introduces novel agents targeting HBV RNA/protein. (Clin Mol Hepatol 2023;29:851-868)
引用
收藏
页码：851 / 868
页数：19
相关论文
共 88 条
[1]   Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update [J].
Ando, Ryoichi ;
Asahina, Yasuhiro ;
Chayama, Kazuaki ;
Hiramatsu, Naoki ;
Ikegami, Toru ;
Izumi, Namiki ;
Kikuchi, Kan ;
Koike, Kazuhiko ;
Kurosaki, Masayuki ;
Mochida, Satoshi ;
Suzuki, Fumitaka ;
Takehara, Tetsuo ;
Takikawa, Hajime ;
Tanaka, Atsushi ;
Tanaka, Eiji ;
Tanaka, Yasuhito ;
Yotsuyanagi, Hiroshi .
HEPATOLOGY RESEARCH, 2020, 50 (08) :892-923
[2]   Cumulative incidence and risk factors for the development of hepatocellular carcinoma in patients with chronic hepatitis B who achieved sustained disappearance of viremia by nucleos(t)ide analog treatment [J].
Ando, Yusuke ;
Ishigami, Masatoshi ;
Ishizu, Yoji ;
Kuzuya, Teiji ;
Honda, Takashi ;
Hayashi, Kazuhiko ;
Ishikawa, Tetsuya ;
Nakano, Isao ;
Hirooka, Yoshiki ;
Goto, Hidemi .
HEPATOLOGY RESEARCH, 2018, 48 (03) :E240-E251
[3]  
[Anonymous], WHO releases first-ever global guidance for country validation of viral hepatitis B and C elimination
[4]   HBV cccDNA-A Culprit and Stumbling Block for the Hepatitis B Virus Infection: Its Presence in Hepatocytes Perplexed the Possible Mission for a Functional Cure [J].
Bhat, Sajad Ahmad ;
Kazim, Syed Naqui .
ACS OMEGA, 2022, 7 (28) :24066-24081
[5]   Host RNA quality control as a hepatitis B antiviral target [J].
Block, Timothy M. ;
Young, John A. T. ;
Javanbakht, Hassan ;
Sofia, Michael J. ;
Zhou, Tianlun .
ANTIVIRAL RESEARCH, 2021, 186
[6]   Pregenomic HBV RNA and Hepatitis B Core-Related Antigen Predict Outcomes in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy [J].
Carey, Ivana ;
Gersch, Jeffrey ;
Wang, Bo ;
Moigboi, Christiana ;
Kuhns, Mary ;
Cloherty, Gavin ;
Dusheiko, Geoffrey ;
Agarwal, Kosh .
HEPATOLOGY, 2020, 72 (01) :42-57
[7]   Serum HBcrAg is better than HBV RNA and HBsAg in reflecting intrahepatic covalently closed circular DNA [J].
Chen, En-Qiang ;
Wang, Meng-Lan ;
Tao, Ya-Chao ;
Wu, Dong-Bo ;
Liao, Juan ;
He, Min ;
Tang, Hong .
JOURNAL OF VIRAL HEPATITIS, 2019, 26 (05) :586-595
[8]   Clinical evaluation of hepatitis B core-related antigen in chronic hepatitis B and hepatocellular carcinoma patients [J].
Chen, Shipeng ;
Jia, Jian'an ;
Gao, Yuzhen ;
Li, Huiming ;
Fang, Meng ;
Feng, Huijuan ;
Guan, Wenqian ;
Ji, Jun ;
Gao, Zhiyuan ;
Gao, Chunfang .
CLINICA CHIMICA ACTA, 2018, 486 :237-244
[9]   Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy [J].
Cheung, K. -S. ;
Seto, W. -K. ;
Wong, D. K. -H. ;
Lai, C. -L. ;
Yuen, M. -F. .
JOURNAL OF VIRAL HEPATITIS, 2017, 24 (08) :654-661
[10]   Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B [J].
Chuaypen, Natthaya ;
Posuwan, Nawarat ;
Payungporn, Sunchai ;
Tanaka, Yasuhito ;
Shinkai, Noboru ;
Poovorawan, Yong ;
Tangkijvanich, Pisit .
LIVER INTERNATIONAL, 2016, 36 (06) :827-836
123456789